Eli Lilly (LLY) said Sunday that its weight-loss drug showed results superior to Novo Nordisk's (NVO) Wegovy in a phase 3 study evaluating the safety and efficacy of the two drugs over 72 weeks in obese or overweight patients with at least one weight-related medical problem and without diabetes.
The company asid Zepbound met its primary endpoint of weight loss, reducing weight by 20.2% or 50.3 pounds compared to 13.7% or 33.1 pounds for Wegovy.
The drug also met all five of its secondary endpoints in the study, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。